Pluristem Therapeutics, Inc. (NASDAQ:PSTI) shares saw unusually-strong trading volume on Monday . Approximately 5,522,771 shares traded hands during mid-day trading, an increase of 2,287% from the previous session’s volume of 231,405 shares.The stock last traded at $1.42 and had previously closed at $1.34.
A number of analysts have recently weighed in on PSTI shares. Maxim Group raised shares of Pluristem Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research note on Monday, June 19th. HC Wainwright set a $4.00 price target on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 17th. Finally, ValuEngine lowered shares of Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $3.19.
The firm’s market cap is $138.41 million. The company has a 50 day moving average price of $1.18 and a 200-day moving average price of $1.28.
An institutional investor recently raised its position in Pluristem Therapeutics stock. Renaissance Technologies LLC grew its holdings in Pluristem Therapeutics, Inc. (NASDAQ:PSTI) by 9.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,553,800 shares of the biotechnology company’s stock after purchasing an additional 129,000 shares during the quarter. Renaissance Technologies LLC owned approximately 1.62% of Pluristem Therapeutics worth $1,911,000 at the end of the most recent reporting period. Institutional investors own 4.47% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Pluristem Therapeutics, Inc. (PSTI) Sees Large Volume Increase” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.chaffeybreeze.com/2017/09/18/pluristem-therapeutics-inc-psti-sees-large-volume-increase.html.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.